Avacta Group Plc’s (AVCT) Corporate Rating Reaffirmed at FinnCap
FinnCap reiterated their corporate rating on shares of Avacta Group Plc (LON:AVCT) in a research note released on Thursday morning. The firm currently has a GBX 200 ($2.60) price target on the biotechnology company’s stock.
Avacta Group Plc (AVCT) traded down 1.31% during midday trading on Thursday, reaching GBX 75.50. 3,000 shares of the company’s stock were exchanged. Avacta Group Plc has a 52 week low of GBX 60.00 and a 52 week high of GBX 103.95. The firm has a 50-day moving average price of GBX 81.61 and a 200 day moving average price of GBX 78.95. The company’s market cap is GBX 51.63 million.
In other Avacta Group Plc news, insider Michael Scott Albin bought 4,345 shares of the business’s stock in a transaction on Tuesday, July 4th. The stock was purchased at an average price of GBX 86 ($1.12) per share, for a total transaction of £3,736.70 ($4,850.97). Also, insider Alastair Smith bought 33,225 shares of the business’s stock in a transaction on Monday, August 21st. The shares were acquired at an average price of GBX 75 ($0.97) per share, with a total value of £24,918.75 ($32,349.41).
Avacta Group Plc Company Profile
Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.
Receive News & Stock Ratings for Avacta Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group Plc and related stocks with our FREE daily email newsletter.